Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
Webcast Chardan Capital Markets 2nd Annual Genetic Medicines Conference (Replay) 10/09/18 at 3:45 p.m. ET
Chardan Capital Markets 2nd Annual Genetic Medicines Conference Tuesday, October 9, 2018 3:45 p.m. ET